Serum free thyroxine levels are associated with the efficacy of weight reduction therapy in obese female patients

Hashimoto, Kazuhito; Tagami, Tetsuya; Muranaka, Kazuya; Tanaka, Masashi; Kono, Shigeo; Shimatsu, Akira; Ogawa, Yoshihiro; Satoh‐Asahara, Noriko

doi:10.1507/endocrj.ej15-0498

Cited by 6 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ab108918; Abcam) to collagen, commercially available ELISA kits were used. The ELISA assays were performed according to the manufacturer's instructions (25). The result was measured at 450 nm in an ELISA reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and finally converted to the affinity of GPVI-Fc-PEG for bovine and mouse collagen.…”

Section: Methodsmentioning

confidence: 99%

GPVI-Fc-PEG improves cerebral infarct volume and cerebral thrombosis in mouse model with cerebral thrombosis

Wufuer

Shan

Magaoweiya

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

Cerebral thrombosis is one of the most common causes of cerebral infarction, and anticoagulation therapy is a routine treatment in patients with hemorrhagic cerebral venous thrombosis. The hemostatic function of platelets is important for the anticoagulation therapy of thrombosis. Glycoprotein VI (GPVI) is reported as the major signaling receptor for collagen and is exclusively expressed on platelets and megakaryocytes, initiating platelet recruitment at sites of vascular injury and demonstrating numerous beneficial effects for patients with cerebral thrombosis. In the present study, thrombus formation and platelet adhesion following endothelial injury was monitored in the jugular vein by intra‑vital fluorescence microscopy. The morphological and clinical observations of cerebral thrombosis were investigated and analyzed in a mouse model with cerebral thrombosis. In addition, the present study investigated the effect of fusion protein GPVI modified with Fc and PEG, which is specifically linked to the extracellular domain of GPVI (GPVI‑Fc‑PEG), on thrombus formation following vessel wall injury and on experimental mice with cerebral thrombosis. The maximum tolerated dose (MTD) was identified as 0.18 mg. GPVI‑Fc‑PEG competitively bound to and prevented von Willebrand Factor‑collagen interactions. The results of the present study demonstrated that cerebral thrombosis was greatly relieved and improved functional outcomes treatment with an MTD of GPVI‑Fc‑PEG following endothelial injury, compared with GPVI‑Fc‑treated mice. In addition, cerebral edema and infarct size was improved compared with GPVI‑Fc‑treated mice with ischemic stroke immediately prior to reperfusion. Furthermore, treatment of GPVI‑Fc‑PEG led to increased reperfusion and improved survival following cerebral thrombosis compared with treatment with either single agent alone. Taken together, GPVI‑Fc‑PEG relieved cerebral thrombosis following ischemic stroke and improved prognostic preclinical outcomes without intracranial bleeding, which suggested that GPVI‑Fc‑PEG may be a potential candidate for cerebral thrombosis therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

GPVI-Fc-PEG improves cerebral infarct volume and cerebral thrombosis in mouse model with cerebral thrombosis

Wufuer

Shan

Magaoweiya

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

Body Weight Reduction and Biochemical Parameters of the Patients After RYGB and SG Bariatric Procedures in 12-Month Observation

et al. 2016

View full text Add to dashboard Cite

BackgroundThe aim of this study was to evaluate the effect of sleeve gastrectomy (SG) and Roux-en-Y-bypass (RYGB) on anthropometric and biochemical parameters, including changes in glucose levels, lipid profile and liver function. Drastic decrease in all lipid fractions a few weeks or months after the surgery could be regarded as favourable, but low level of HDL is an independent risk factor for heart diseases. Extreme load on the liver without preparation of the patient to the surgery can have negative consequences.MethodsThe test group comprised of 40 female patients at the age of 42.96 with average body weight of 131.56 kg and BMI 46.49. Biochemical analyses were performed using calorimetric method.ResultsNo statistically significant differences were observed in glucose levels between the two types of procedures. The highest differences were noted for triglycerides levels, which decreased, as well as all cholesterol fractions, after RYGB, but were increasing during the first months after SG procedure. Changes in lipid profile, caused by the reduction of all lipid fractions, were more visible after RYGB. The decrease in total cholesterol directly and activity of liver enzymes after the procedure was as higher after RYGB as after SG. Increased activity of transaminases indicates significant liver overload.ConclusionsWith the selection of groups of patients with similar initial parameters, it is not clear whether the differences between the two procedures when assessing the improvement of glycaemia are significant. However, due to invasive character of RYGB, liver overload lasting several months and lifelong limited absorption of nutrients, the possibility of SG procedure should be considered as a first option.

show abstract

Free T4 is associated with exenatide-related weight loss in patients with type 2 diabetes mellitus and obesity

Topaloğlu

TOKSÖZ>

2023

Int J Diabetes Dev Ctries

View full text Add to dashboard Cite

Serum free thyroxine levels are associated with the efficacy of weight reduction therapy in obese female patients

Cited by 6 publications

References 26 publications

GPVI-Fc-PEG improves cerebral infarct volume and cerebral thrombosis in mouse model with cerebral thrombosis

GPVI-Fc-PEG improves cerebral infarct volume and cerebral thrombosis in mouse model with cerebral thrombosis

Body Weight Reduction and Biochemical Parameters of the Patients After RYGB and SG Bariatric Procedures in 12-Month Observation

Free T4 is associated with exenatide-related weight loss in patients with type 2 diabetes mellitus and obesity

Contact Info

Product

Resources

About